ライフサイエンスコーパス: olanzapine

1 ss-reactivity with clozapine metabolites and olanzapine.

2 d with the most widely used medication, oral olanzapine.

3 ence of baseline severity on the efficacy of olanzapine.

4 spectrum disorders treated with clozapine or olanzapine.

5 iapine (HR, 1.34; 95% CI, 1.07-1.69) but not olanzapine.

6 07; P = .001) but not quetiapine fumarate or olanzapine.

7 ivity, as well as response to treatment with olanzapine.

8 6145 were one-fifth as likely to discontinue olanzapine.

9 c, haloperidol or an atypical antipsychotic, olanzapine.

10 n of the atypical neuroleptics clozapine and olanzapine.

11 ble change in HDL cholesterol and girth with olanzapine.

12 a distinct mechanism different from that of olanzapine.

13 admission (30.8%) among neonates exposed to olanzapine.

14 onist, mitigates weight gain associated with olanzapine.

15 izophrenia patients chronically treated with olanzapine.

16 n the study group additionally received oral olanzapine 0.14 mg/kg/day (rounded to the nearest 2.5 mg

17 0.33 mg/kg, IP) and the efficacious dose of olanzapine (0.033 mg/kg, IP) in combination with either

18 1.27-2.82, p=0.002), but not those receiving olanzapine (0.32, 0.21-0.49, p<0.0001).

19 sulpride (SMD -0.37, 95% CI -0.61 to -0.14), olanzapine (-0.25, -0.39 to -0.12), ziprasidone (-0.25,

20 e CATIE neurocognitive battery were 0.17 for olanzapine, 0.33 for quetiapine, and 0.32 for risperidon

21 of Cognition in Schizophrenia were 0.19 for olanzapine, 0.34 for quetiapine, and 0.22 for risperidon

22 done (1.7%; 95% CI, 0.6%-2.8%; P = .003) and olanzapine (1.5%; 95% CI, 0.02%-3.0%; P = .047).

23 d maintained stability on an oral regimen of olanzapine (10, 15, or 20 mg/day) for 4 to 8 weeks were

24 ular olanzapine or haloperidol injection=62, olanzapine=144, placebo=75, quetiapine=125, risperidone=

25 3.2 mg; lurasidone, 147 mg/day and 23.5 mg; olanzapine, 15.2 mg/day and 2.4 mg; olanzapine LAI, 277

26 were administered the atypical antipsychotic olanzapine (2.5 mg/kg) twice daily for 28 days.

27 Subjects received either olanzapine (2.5-20 mg/day [N=107]) or placebo (N=54).

28 nts were randomly assigned to treatment with olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day),

29 oaffective disorder to treatment with either olanzapine (2.5-20 mg/day), risperidone (0.5-6 mg/day),

30 ding order were 2.79 (95% CI, 1.97-3.96) for olanzapine, 2.46 (95% CI, 1.94-3.12) for risperidone, an

31 P < .01) with an NNH of 27 (95% CI, 19-46); olanzapine, 2.5% (95% CI, 0.3%-4.7%; P = .02) with an NN

32 nt groups in response rates (molindone: 50%; olanzapine: 34%; risperidone: 46%) or magnitude of sympt

33 ontained data for 939 patients (552 received olanzapine; 387 received placebo).

34 y examining two drug samples, Olanzapine and Olanzapine-4' N-oxide.

35 roate (392; 95% CI, 334-460 per 10000 PYAR), olanzapine (409; 95% CI, 345-483 per 10000 PYAR), or que

36 odal prescribed daily doses were 11.7 mg for olanzapine, 506 mg for quetiapine, and 2.4 mg for risper

37 2.9%) than with 40 mg of lurasidone (11.8%), olanzapine (7.4%), or placebo (0.9%).

38 Like clozapine, olanzapine acts via alpha7 nicotinic receptors to elicit

39 Although olanzapine alleviated cognitive deficits produced by neo

40 Similar to results from a past study, olanzapine alleviated cognitive impairment on the MWM pl

41 tory processing deficit, were obtained after olanzapine alone (0.01, 0.033, 0.1, 0.33 mg/kg, IP) and

42 We found that olanzapine, an AAP highly associated with weight gain, c

43 This effect was blocked by olanzapine, an antagonist of 5-HT1/2A receptors.

44 Thirteen participants (20.3%) randomized to olanzapine and 34 (54.8%) to placebo experienced a relap

45 y-five participants were assigned to receive olanzapine and 77 to receive placebo.

46 ics in terms of metabolic side-effects, with olanzapine and clozapine exhibiting the worst profiles a

47 receive treatment with either ziprasidone or olanzapine and followed for 1 year by unblinded investig

48 efully consider the benefit-to-risk ratio of olanzapine and its additional, prophylactic effect again

49 od was tested by examining two drug samples, Olanzapine and Olanzapine-4' N-oxide.

50 ter the magnitude of the differences between olanzapine and placebo was expected.

51 s associated with weight gain in women, with olanzapine and quetiapine in particular, and with unfavo

52 Olanzapine and quetiapine treatments were significantly

53 With olanzapine and quetiapine, respectively, mean levels inc

54 reater in the perphenazine group than in the olanzapine and risperidone groups.

55 n the Clinical Global Impression of Changes, olanzapine and risperidone on the Brief Psychiatric Rati

56 Olanzapine and risperidone showed declining rates and qu

57 Olanzapine and risperidone were associated with signific

58 ety of two second-generation antipsychotics (olanzapine and risperidone) with a first-generation anti

59 to receive either combination treatment with olanzapine and samidorphan or olanzapine treatment for 2

60 d when clozapine treatment was compared with olanzapine and the medium control.

61 A combination of olanzapine and the opioid receptor antagonist samidorpha

62 Two monkeys were impaired after 0.1 mg/kg olanzapine and two were impaired after 0.3 mg/kg deschlo

63 maller increases in waist circumference than olanzapine and was well tolerated.

64 c drugs (APDs), e.g. clozapine, risperidone, olanzapine and ziprasidone, to improve cognitive functio

65 , 1670 prescribed valproate, 1477 prescribed olanzapine, and 1376 prescribed quetiapine as maintenanc

66 ents who could be evaluated (192 assigned to olanzapine, and 188 to placebo).

67 ctions of three DREADD actuators, clozapine, olanzapine, and deschloroclozapine, in four male rhesus

68 idazolam, clozapine, terfenadine, erlotinib, olanzapine, and moxifloxacin) in multiple tissues after

69 rigine, topiramate, valproate, aripiprazole, olanzapine, and omega-3 fatty acid supplementation.

70 prescribed lithium, those taking valproate, olanzapine, and quetiapine had reduced rates of chronic

71 lamotrigine, lamotrigine+valproate, lithium, olanzapine, and quetiapine outperformed placebo for RR-d

72 f greater than 15% weight gain on valproate, olanzapine, and quetiapine were higher (valproate HR 1.6

73 es during treatment with lithium, valproate, olanzapine, and quetiapine.

74 sychotics other than clozapine, haloperidol, olanzapine, and risperidone.

75 .12 and 0.20 were observed for aripiprazole, olanzapine, and risperidone.

76 ant benefits were observed for aripiprazole, olanzapine, and risperidone.

77 reatment of affective disorders (quetiapine, olanzapine, and semisodium valproate) during the same pe

78 s, specifically quetiapine, risperidone, and olanzapine, are known to cause acute kidney injury (AKI)

79 gain or psychiatric disease, we administered olanzapine, aripiprazole, or placebo for 9 days to healt

80 also analyzed time to discontinuation in the olanzapine arm of the CATIE study.

81 monstrating efficacy similar to that of oral olanzapine as well as to each other.

82 Olanzapine, as compared with placebo, significantly impr

83 the efficacy of olanzapine while mitigating olanzapine-associated weight gain.

84 also activated with N-desmethylclozapine and olanzapine at supratherapeutic concentrations.

85 isk also received aprepitant with or without olanzapine, based on their risk level.

86 1 binding clefts revealed that clozapine and olanzapine bind in a similar conformation to the P4-P6 p

87 to the therapeutic effects of clozapine and olanzapine, both highly effective therapeutics with sign

88 Lithium, quetiapine, olanzapine, bupropion, and carbamazepine were associated

89 haloperidol, aripiprazole, risperidone, and olanzapine, but, again, evidence was very low to low qua

90 INTERPRETATION: Benefits of olanzapine can be expected for patients across the full

91 Long-term treatment of olanzapine caused metabolic symptoms, including IR, by m

92 A pattern of superiority for olanzapine, clozapine, and risperidone was seen in other

93 f life, except for worsened functioning with olanzapine compared to placebo.

94 This study evaluated the benefits of olanzapine compared with placebo for adult outpatients w

95 dy documented a modest therapeutic effect of olanzapine compared with placebo on weight in adult outp

96 ion in remission, continuing sertraline plus olanzapine compared with sertraline plus placebo reduced

97 ate that one of the two symmetry elements of olanzapine crystals, an inversion centre, emerges in sol

98 Risperidone and olanzapine did not demonstrate superior efficacy over mo

99 e rate was also significantly increased with olanzapine during the three periods: 86% versus 65% (P<0

100 ll patients seem to benefit less in terms of olanzapine efficacy, but still experience the same side-

101 weeks, with a safety profile similar to oral olanzapine except for injection-related adverse events.

102 Collectively, our studies suggest that olanzapine exerts some of its untoward metabolic effects

103 amate continued to produce positive results, olanzapine failed to show superior outcomes compared wit

104 ents included weight gain (particularly with olanzapine), fatigue, sedation, akathisia (for aripipraz

105 treatment also improved glucose tolerance in olanzapine-fed mice.

106 ern antipsychotics (particularly lurasidone, olanzapine + fluoxetine, and quetiapine) and the anticon

107 tified 14 short-term trials of aripiprazole, olanzapine/fluoxetine combination (OFC), quetiapine, and

108 treatment-resistant depression (TRD) taking olanzapine/fluoxetine combination (OFC).

109 ically important benefit of haloperidol over olanzapine for improving positive symptoms, but the bene

110 We examined the efficacy of olanzapine for the prevention of nausea and vomiting in

111 y was to evaluate the efficacy and safety of olanzapine for the treatment of acute manic or mixed epi

112 ression acutely treated with sertraline plus olanzapine for up to 12 weeks and met criteria for remis

113 ariprazine to 0.20 mmol/L (0.14 to 0.26) for olanzapine; for HDL cholesterol from 0.05 mmol/L (0.00 t

114 loperidol to 1.07 kg/m(2) (0.90 to 1.25) for olanzapine; for total-cholesterol from -0.09 mmol/L (-0.

115 increase in BMI over time was greater in the olanzapine group (0.259 [SD=0.051] compared with 0.095 [

116 Grade 1/2 somnolence was greater in the olanzapine group (35% v 11%; P < .001).

117 samidorphan group and 6.59% (SE=0.67) in the olanzapine group (the difference of -2.38% [SE=0.76] was

118 A higher proportion of patients in the olanzapine group achieved CR in the acute period (78% v

119 idorphan combination group compared with the olanzapine group had weight gain >=10% (17.8% and 29.8%,

120 th no nausea was significantly higher in the olanzapine group in the acute period (74% v 52%; P < .00

121 he lurasidone groups combined, 34.4% for the olanzapine group, and 7.0% for the placebo group.

122 for the lurasidone groups compared with the olanzapine group.

123 idorphan combination group compared with the olanzapine group.

124 d between the long-acting injection and oral olanzapine groups in general safety parameters.

125 he groups) in the olanzapine/samidorphan and olanzapine groups included weight gain (24.8% and 36.2%)

126 ade 5 toxic effects, some patients receiving olanzapine had increased sedation (severe in 5%) on day

127 ia, and antipsychotics such as clozapine and olanzapine have been associated with differences in gene

128 New prescriptions of olanzapine (higher metabolic risk) declined during the w

129 proate HR 0.24; 95% CI 0.09-0.61; p = 0.003, olanzapine HR 0.31; 95% CI 0.13-0.73; p = 0.007) and hyp

130 proate HR 0.25; 95% CI 0.10-0.60; p = 0.002, olanzapine HR 0.32; 95% CI 0.14-0.76; p = 0.008, quetiap

131 nfidence interval [CI] 0.45-0.69; p < 0.001, olanzapine HR 0.57; 95% CI 0.45-0.71; p < 0.001, quetiap

132 proate HR 1.62; 95% CI 1.31-2.01; p < 0.001, olanzapine HR 1.84; 95% CI 1.47-2.30; p < 0.001, quetiap

133 e (HR 0.60; 95% CI 0.40-0.89; p = 0.012) and olanzapine (HR 0.48; 95% CI 0.29-0.77; p = 0.003), compa

134 % CI, 0.52-0.65), and long-acting injectable olanzapine (HR, 0.58; 95% CI, 0.44-0.77) compared with n

135 Other important findings address olanzapine in adults and fosaprepitant in pediatric pati

136 on now includes the option of a 5-mg dose of olanzapine in adults and intravenous formulations of apr

137 ated, randomized, open-label trial evaluated olanzapine in children (ages 5-18 years) scheduled to re

138 Example images are shown for olanzapine in kidney and liver and imatinib in glioma.

139 ombined olanzapine/samidorphan compared with olanzapine in patients with schizophrenia.

140 tality rates associated with ziprasidone and olanzapine in real-world use.

141 ed risk of nonsuicidal mortality relative to olanzapine in real-world use; the study excludes a relat

142 as superior to risperidone, haloperidol, and olanzapine in terms of weight gain, and superior to risp

143 d with the exception of the option of adding olanzapine in the setting of hematopoietic stem cell tra

144 f lurasidone, 120 mg of lurasidone, 15 mg of olanzapine (included to test for assay sensitivity), or

145 alanced against potential adverse effects of olanzapine, including weight gain.

146 e used an experimental model that reproduces olanzapine-induced hyperphagia and obesity in female C57

147 Furthermore, olanzapine-induced hyperphagia and weight gain were blun

148 HTR2C-specific agonist lorcaserin suppressed olanzapine-induced hyperphagia and weight gain.

149 e of the components p50/p65 of NF-kB rescued olanzapine-induced IR in NIH-3T3 L1-derived adipocytes.

150 of combining olanzapine with samidorphan on olanzapine-induced weight gain, and to assess the overal

151 Our findings demonstrate that olanzapine induces inflammatory cytokine reactions in pe

152 Olanzapine is a second-generation anti-psychotic drug us

153 Olanzapine is recommended in adult patients for the prev

154 23.5 mg; olanzapine, 15.2 mg/day and 2.4 mg; olanzapine LAI, 277 mg every 2 weeks and 3.2 mg; paliper

155 The study had a 1-week open-label olanzapine lead-in period followed by a 12-week double-b

156 However, the long-term administration of olanzapine leads to insulin resistance (IR); the mechani

157 All SGAs+LIT/VALs other than olanzapine+LIT/VAL outperformed placebo+LIT/VAL for RR-a

158 ting injection; a very low reference dose of olanzapine long-acting injection (45 mg every 4 weeks; N

159 to evaluate the efficacy and tolerability of olanzapine long-acting injection for maintenance treatme

160 Olanzapine long-acting injection was efficacious in main

161 pine-treated patients (93%), as well as most olanzapine long-acting injection-treated patients receiv

162 high" (300 mg every 2 weeks; N=141) doses of olanzapine long-acting injection; a very low reference d

163 d 8% for the high, medium, low, and very low olanzapine long-acting treatment groups, respectively.

164 4R agonist xanomeline, or the antipsychotics olanzapine (M1R antagonist) and haloperidol (low M1R aff

165 EXPOSURES Patients received olanzapine monotherapy for 8 weeks.

166 combination treatment was similar to that of olanzapine monotherapy.

167 ed lithium (n = 2148), valproate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376) as maint

168 of patients with schizophrenia treated with olanzapine (n = 167).

169 onfidence interval [CI], 7.4 to 9.7 kg) with olanzapine (n = 45), by 6.1 kg (95% CI, 4.9 to 7.2 kg) w

170 ticipants were randomized either to continue olanzapine (n = 64) or switch from olanzapine to placebo

171 ks; N=144); or their stabilized dose of oral olanzapine (N=322).

172 0.91 for ziprasidone (N=9,077) and 0.90 for olanzapine (N=9,077).

173 (olanzapine/samidorphan combination, N=280; olanzapine, N=281), 538 had at least one postbaseline we

174 done), extrapyramidal symptoms (NNH = 10 for olanzapine; NNH = 20 for risperidone), and urinary tract

175 Atypical antipsychotics such as olanzapine often induce excessive weight gain and type 2

176 ed dosages; 32.1% received prescriptions for olanzapine (often at high dosages), 23.3% for more than

177 etine (4 weeks) or subchronic treatment with olanzapine (OLZ) (1 week) on ABA in BALB/cJ mice.

178 micromol/kg twice a day s.c. for 3 days) or olanzapine (OLZ) (4 to 15 micromol/kg twice a day for 3

179 Olanzapine (OLZ) is an atypical antipsychotic whose clin

180 ies of hydrophobic surface modifications for olanzapine (OLZ) loading by physical absorption to produ

181 at minocycline (MINO) co-treatment abrogates olanzapine (OLZ)-induced hyperphagia and weight gain in

182 difference between effects of clozapine and olanzapine on cortical thickness.

183 There was worsening with olanzapine on the BPRS withdrawn depression factor.

184 The effect of olanzapine on the daily rate of anthropometric and metab

185 weeks) treatment with either haloperidol or olanzapine on the rat cortex.

186 Olanzapine only activates TCC at supratherapeutic concen

187 s were significant compared with placebo for olanzapine only.

188 (2A) by antipsychotics, such as risperidone, olanzapine or chlorpromazine prevented it.

189 promazine=13, haloperidol=316, intramuscular olanzapine or haloperidol injection=62, olanzapine=144,

190 randomly assigned in a 1:1 ratio to receive olanzapine or placebo and were seen weekly for 16 weeks.

191 n in phase 1 showed greater improvement with olanzapine or risperidone on the Neuropsychiatric Invent

192 monkeys chronically exposed to haloperidol, olanzapine, or placebo were also conducted.

193 rder who were prescribed lithium, valproate, olanzapine, or quetiapine as maintenance mood stabilizer

194 [HR], 1.40; 95% CI, 1.12-1.74 for valproate, olanzapine, or quetiapine vs lithium) and PS matching (H

195 m 18 macaque monkeys exposed to haloperidol, olanzapine, or sham long-term.

196 The two groups received either 10 mg of olanzapine orally or matching placebo daily on days 1 th

197 nce showed a clinically important benefit of olanzapine over haloperidol in improving negative sympto

198 ienced sedation and delirium consistent with olanzapine overdose following possible accidental intrav

199 neurocognitive improvements of z = 0.13 for olanzapine (P<.002), 0.25 for perphenazine (P<.001), 0.1

200 m, lithium+oxcarbazepine, lithium+valproate, olanzapine, paliperidone, quetiapine, risperidone long-a

201 on antipsychotics-aripiprazole, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, rispe

202 Intervention Target doses of 15 to 20 mg of olanzapine per day plus masked sertraline or placebo at

203 , patients were randomly assigned to receive olanzapine, perphenazine, quetiapine, risperidone, or zi

204 higher remission rates during the trial than olanzapine/placebo (odds ratio [OR], 1.28; 95% confidenc

205 to receive olanzapine plus placebo (N=75) or olanzapine plus 5 mg (N=80), 10 mg (N=86), or 20 mg (N=6

206 rospectively compared combination therapy of olanzapine plus either samidorphan or placebo for the tr

207 domly assigned in a 1:1:1:1 ratio to receive olanzapine plus placebo (N=75) or olanzapine plus 5 mg (

208 ine in body weight was 4.1% (2.9 kg) for the olanzapine plus placebo group and 2.6% (1.9 kg) for the

209 ring at a rate >=2 times greater than in the olanzapine plus placebo group were somnolence, sedation,

210 e olanzapine plus samidorphan groups and the olanzapine plus placebo group.

211 ht gain (37% lower weight gain compared with olanzapine plus placebo).

212 e plus samidorphan was equivalent to that of olanzapine plus placebo, and olanzapine plus samidorphan

213 lanzapine plus samidorphan was comparable to olanzapine plus placebo, to assess the effect of combini

214 cant mitigation of weight gain compared with olanzapine plus placebo.

215 tolerated, with a safety profile similar to olanzapine plus placebo.

216 plus placebo group and 2.6% (1.9 kg) for the olanzapine plus samidorphan group (2.8% [2.1 kg] for the

217 s reported at a frequency >=5% in any of the olanzapine plus samidorphan groups and occurring at a ra

218 safety measures were comparable between the olanzapine plus samidorphan groups and the olanzapine pl

219 al, multicenter, randomized phase 2 study of olanzapine plus samidorphan in patients with schizophren

220 Treatment with olanzapine plus samidorphan resulted in a statistically

221 lent to that of olanzapine plus placebo, and olanzapine plus samidorphan was associated with clinical

222 o confirm that the antipsychotic efficacy of olanzapine plus samidorphan was comparable to olanzapine

223 The antipsychotic efficacy of olanzapine plus samidorphan was equivalent to that of ol

224 Olanzapine plus samidorphan was generally well tolerated

225 ssess the overall safety and tolerability of olanzapine plus samidorphan.

226 All doses of olanzapine produced improved P20-N40 inhibitory processi

227 nts were randomly assigned to treatment with olanzapine, quetiapine fumarate, risperidone, or placebo

228 Olanzapine, quetiapine, and risperidone all produced sig

229 Olanzapine, quetiapine, and risperidone demonstrated com

230 sured by treatment discontinuation rates) of olanzapine, quetiapine, and risperidone in patients earl

231 The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in

232 The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitiv

233 nd-generation antipsychotics (eg, clozapine, olanzapine, quetiapine, and risperidone) are associated

234 As a group, the atypical antipsychotics (olanzapine, quetiapine, and risperidone) showed a dose-r

235 f second-generation antipsychotic use (i.e., olanzapine, quetiapine, and risperidone) throughout the

236 scription for an antipsychotic (haloperidol, olanzapine, quetiapine, and risperidone), valproic acid

237 justed absolute change in mortality risk for olanzapine, quetiapine, and risperidone.

238 Asenapine, lithium, olanzapine, quetiapine, and valproate outperformed place

239 pies (SGAs) (i.e., aripiprazole, lurasidone, olanzapine, quetiapine, and ziprasidone) with lithium or

240 pical antipsychotic medication (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, asena

241 reatment with an antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) or valproic acid

242 Treatment with aripiprazole, olanzapine, quetiapine, or risperidone for 12 weeks.

243 ial examining the strategy of switching from olanzapine, quetiapine, or risperidone to aripiprazole t

244 /dl who were on a stable treatment dosage of olanzapine, quetiapine, or risperidone were randomly ass

245 Piracetam, amantadine, selegiline, olanzapine, quetiapine, risperidone, and citalopram do n

246 prazole, asenapine, iloperidone, lurasidone, olanzapine, quetiapine, risperidone, and ziprasidone.

247 omly to masked, flexible-dose treatment with olanzapine, quetiapine, risperidone, or placebo for up t

248 ly assigned to receive masked, flexible-dose olanzapine, quetiapine, risperidone, or placebo.

249 gnificantly greater in patients treated with olanzapine relative to patients receiving placebo.

250 8-1.73) followed by risperidone (reference), olanzapine (relative risk=0.99, 95% CI=0.89-1.10), valpr

251 e, aripiprazole, chlorpromazine, quetiapine, olanzapine, risperidone, and ziprasidone all potently an

252 verse events (in >=10% of the groups) in the olanzapine/samidorphan and olanzapine groups included we

253 s in waist circumference were smaller in the olanzapine/samidorphan combination group compared with t

254 Significantly fewer patients in the olanzapine/samidorphan combination group compared with t

255 Olanzapine/samidorphan combination treatment was associa

256 Of 561 patients who underwent randomization (olanzapine/samidorphan combination, N=280; olanzapine, N

257 ors evaluated the weight profile of combined olanzapine/samidorphan compared with olanzapine in patie

258 nge from baseline was 4.21% (SE=0.68) in the olanzapine/samidorphan group and 6.59% (SE=0.67) in the

259 Treatment with olanzapine/sertraline was associated with higher remissi

260 ically among these patients, amisulpride and olanzapine showed superior efficacy versus haloperidol,

261 Olanzapine showed the greatest risk of weight gain and s

262 Olanzapine significantly improved CR rates for vomiting

263 For amisulpride and olanzapine, specific data for patients with predominant

264 nduced nausea was significantly greater with olanzapine than with placebo in the first 24 hours after

265 ed controlled trial demonstrated that adding olanzapine to antiemetic prophylaxis reduces the likelih

266 endation Key updates include the addition of olanzapine to antiemetic regimens for adults who receive

267 continue olanzapine (n = 64) or switch from olanzapine to placebo (n = 62).

268 ithium, as were rates of hypertension in the olanzapine treated group (HR 1.41, 95% CI 1.06-1.87; p =

269 At 24 weeks, the majority of oral olanzapine-treated patients (93%), as well as most olanz

270 We found that olanzapine treatment acutely increased food intake, impa

271 treatment with olanzapine and samidorphan or olanzapine treatment for 24 weeks.

272 ividuals, and response to an 8-week trial of olanzapine treatment in patients with schizophrenia.

273 induced by olanzapine, we found that chronic olanzapine treatment induces differential inflammatory c

274 tral nervous system and suggest that chronic olanzapine treatment of schizophrenia patients may cause

275 or agonist liraglutide added to clozapine or olanzapine treatment of schizophrenia spectrum disorders

276 ood olanzapine treatment, although adulthood olanzapine treatment produced a significant increase in

277 expression that were unaffected by adulthood olanzapine treatment, although adulthood olanzapine trea

278 Starting 1 day after the end of olanzapine treatment, animals were behaviorally tested o

279 uated improvement in negative symptoms after olanzapine treatment.

280 d MetS by a combination of high-fat diet and olanzapine treatment.

281 ased incidence of the metabolic syndrome for olanzapine versus haloperidol (risk differences, 2% and

282 g Scale (YMRS; range 0-60) up to 3 weeks for olanzapine versus placebo groups using eight increasingl

283 nts with a baseline score of 20-25 (9.26 for olanzapine vs 6.70 for placebo; effect size 0.35, 95% CI

284 IQR], 150-200 mg/d) and the median dosage of olanzapine was 15 mg/d (IQR, 10-20 mg/d).

285 4R agonist xanomeline and the M1R antagonist olanzapine was able to inhibit (123)I-iododexetimide ex

286 Olanzapine was associated with at least one use of drugs

287 atment with both doses of lurasidone or with olanzapine was associated with significantly greater imp

288 ation observed after the 0.033 mg/kg dose of olanzapine was due to a selective decrease in response t

289 zed mean difference; 95% credible interval), olanzapine was more effective than quetiapine (-0.29; -0

290 In addition, olanzapine was significantly associated with decreases i

291 In multivariable analyses, olanzapine was significantly associated with higher trig

292 Olanzapine was superior to haloperidol and risperidone f

293 cellular and rodent models of IR induced by olanzapine, we found that chronic olanzapine treatment i

294 received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabete

295 tment is intended to provide the efficacy of olanzapine while mitigating olanzapine-associated weight

296 sses whether another atypical antipsychotic, olanzapine, will also improve sensory inhibition deficit

297 , randomised controlled trials that compared olanzapine with placebo, identified through searches of

298 ed, double-blind, phase 3 trial, we compared olanzapine with placebo, in combination with dexamethaso

299 s placebo, to assess the effect of combining olanzapine with samidorphan on olanzapine-induced weight

300 Lithium, venlafaxine, bupropion, quetiapine, olanzapine, ziprasidone, valproic acid, carbamazepine, a